Pressure BioSciences, Inc. Announces Record Revenue, Significant Increase in Consumable Sales for the Second Quarter 2010

SOUTH EASTON, Mass., Aug. 17, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" or the "Company") today announced strong financial results for the three and six month periods ended June 30 2010, and provided a brief business update.

Total revenue for the second quarter of 2010 was $402,104 compared to $270,381 for the comparable period in 2009, a 49% increase. Revenue from the sale of PCT products and services was $283,382 for the three months ended June 30, 2010 compared to $159,202 for the same period in 2009, a 78% increase. During each of Q2 2010 and 2009, the Company completed the installation of 12 Pressure Cycling Technology (PCT) Sample Preparation Systems (PCT Systems). Eight PCT Systems installed during Q2 2010 were purchased and four were leased, as compared to six purchases and six leases during Q2 2009. All 12 installations in Q2 2010 were domestic placements, compared to nine domestic and three international installations in Q2 2009. Sales of PCT-based consumables generated revenue of approximately $33,000 for the three months ended June 30, 2010 compared to approximately $15,000 for the same period in 2009, an increase of approximately 120%.

Operating loss for Q2 2010 was $797,667 compared to $815,333 for the same period in 2009. After the exclusion of non-cash charges, operating cash burn for the second quarter of 2010 was approximately $693,000, compared to approximately $663,000 for the second quarter of 2009, an increase of about 5%.

Total revenue for the six months ended June 30, 2010 was $692,917 compared to $577,143 for the same period in 2009, a 20% increase. Revenue from the sale of PCT products and services was $472,532 for the six months ended June 30, 2010 compared to $381,344 for the same period in 2009, a 24% increase. During each of the first six months of 2010 and 2009, the Company installed 22 PCT Systems. Twelve of the PCT Systems installed during the first six months of 2010 were purchased and 10 were leased, as compared to 13 purchases and nine leases during the same period in 2009. All of the installations during the first six months of 2010 were domestic compared to 16 domestic and six international installations for the same period in 2009. Sales of PCT-based consumables generated revenue of $59,327 for the six months ended June 30, 2010 compared to $41,040 for the same period in 2009, a 45% increase.

Operating loss for the six months ended June 30, 2010 was $1,709,098 compared to $1,665,244 for the same period in 2009. After the exclusion of non-cash charges, operating cash burn for the six months ended June 30, 2010 was approximately $1,445,000, compared to approximately $1,318,000 for the same period in 2009, an increase of about 10%.

Loss per common share -- basic and diluted -- was $0.35 for the second quarter of 2010 compared to $0.39 for the second quarter of 2009. Loss per common share -- basic and diluted -- was $0.80 for the six months ended June 30, 2010 compared to $0.71 for the same six month period of 2009. The loss per common share for the six months ended June 30, 2009 included an income tax refund of $623,262.

Joseph L. Damasio, Jr., Corporate Controller, commented: "We continue to run the Company with an eye towards frugality, all the while doing our best not to put undue pressure on operating activities. To that end, we have been successful in controlling our operating cash burn. Operating cash usages for the three and six month periods ended June 30, 2010 were approximately 5% and 10% higher than for the same periods in 2009, respectively. This increase was due primarily to additional patent related expenses incurred in the protection of our PCT platform, investor relations costs, and marketing and sales activities -- especially the recent Harvard Medical School Symposium on Ultra-high Pressure."

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., said: "We reported a number of significant achievements during the second quarter of 2010, and during the weeks since, most notably:

  --  We added two distinguished members to our Board of Directors (Mr. Alan
      Goldberg and Mr. Greg Freitag) who together offer many years of
      experience helping small public companies grow.

  --  Exercise of the February 2009 Series A Warrants, netting over $1.2
      million to PBI in Q2 2010

  --  A symposium on May 21st at Harvard Medical School on the Applications of
      Ultra-high Pressure in Biotechnology. The Symposium, co-hosted by
      several Harvard groups, included presentations on the advantages of PCT
      by 14 scientists from prestigious laboratories in North America.

  --  A highlight of PCT in the August issues of two leading biotechnology
      publications with worldwide readership and importance."

Mr. Schumacher continued: "Our record revenue in the second quarter came from the hard, diligent work of the entire PBI staff, and from a concerted effort to increase consumable usage from existing customers. We also focused on improving the ratio of instrument sales verses leases because we believed that increasing this ratio would improve both cash flows and margins, and it did. Consequently, we will continue to work towards further improvements in this ratio in the future."

Mr. Schumacher concluded: "Our goal is to gain market acceptance of our powerful PCT platform by driving the installed base of instrument users, especially among prestigious, well-known scientists who are known to publish and present their research results often. We believe the more that our powerful PCT --based platform is discussed in scientific circles, the faster we will reach our goal of market acceptance. To that end, there have been more publications and presentations on our PCT-based platform during the first six months of 2010 than there were in almost all of 2009. We believe this increase in scientific outreach, plus the record revenue of Q2 2010, is an indication that we are beginning to attain market acceptance. We therefore expect to continue this focused strategy into the future."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed publicly traded company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements that 2010 revenue and installations may exceed those reported in 2009; that we will achieve market acceptance of PCT; that presentations and publications of data generated with the PCT Systems will lead to greater market acceptance; that improving the ratio of instruments sales to leases will improve cash flows and margins; and the anticipated advantages and benefits of the Company's products and technology as presented at the Harvard Symposium; and that scientific publications and presentations will help the Company grow towards profitability in the future. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the Company's financial results for the quarter and six months ended June 30, 2010 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customer's needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen costs or cost increases; the risk that the Company may be unable to improve total revenue and PCT products and services revenue, the number of PCT Systems installations, and its operating loss because potential customers may not believe that the PCT System will provide any significant advantages over other sample preparation systems and due to unexpected costs or increases in costs and therefore the Company will need additional capital sooner than anticipated; possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of PCT; changes in customer's needs and technological innovations; that other scientists may not be able to corroborate the data generated by third party labs that have been previously reported at the Harvard Symposium on May 21 or that are otherwise published or presented publicly; and the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the first quarter of 2011. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

  Consolidated Statements of
   Operations

  (Unaudited)                    For the Three Months Ended     For the Six Months Ended
                                          June 30,                      June 30,
                                 --------------------------  ------------------------------

                                     2010          2009           2010            2009
                                 ------------  ------------  --------------  --------------

  REVENUE:
   PCT Products, services,
    other                           $ 283,382     $ 159,202       $ 472,532       $ 381,344

   Grant revenue                      118,722       111,179         220,385         195,799
                                 ------------  ------------  --------------  --------------

    Total revenue                     402,104       270,381         692,917         577,143
                                 ------------  ------------  --------------  --------------

  COSTS AND EXPENSES:
   Cost of PCT products and
    services                          126,972        90,820         214,075         231,063
   Research and development           304,143       315,046         598,284         622,270
   Selling and marketing              294,275       252,464         576,853         530,880

   General and administrative         474,381       427,384       1,012,803         858,174
                                 ------------  ------------  --------------  --------------
    Total operating costs and
     expenses                       1,199,771     1,085,714       2,402,015       2,242,387
                                 ------------  ------------  --------------  --------------

    Operating loss                  (797,667)     (815,333)     (1,709,098)     (1,665,244)


   Interest income                      1,016         1,284           1,122           3,687
                                 ------------  ------------  --------------  --------------

    Loss before income taxes        (796,651)     (814,049)     (1,707,976)     (1,661,557)

    Income tax refund                      --            --              --         623,262
                                 ------------  ------------  --------------  --------------

   Net loss                         (796,651)     (814,049)     (1,707,976)     (1,038,295)
                                 ------------  ------------  --------------  --------------
   Accrued and deemed dividends
    on convertible preferred
    stock                           (127,839)      (33,880)       (384,363)       (523,683)
                                 ------------  ------------  --------------  --------------
   Net loss applicable to
    common shareholders           $ (924,490)   $ (847,929)   $ (2,092,339)   $ (1,561,978)
                                 ============  ============  ==============  ==============


   Net loss per share
    attributable to common
    stockholders - basic and
    diluted                          $ (0.35)      $ (0.39)        $ (0.80)        $ (0.71)

   Weighted average common
    stock shares outstanding
    used in the basic and
    diluted net loss per share
    calculation                     2,621,291     2,195,283       2,615,557       2,195,283

  Consolidated Balance Sheets
  (Unaudited)

                                              December 31,
             ASSETS            June 30, 2010      2009
                               -------------  ------------
  CURRENT ASSETS
   Cash and cash equivalents     $ 1,677,354   $ 1,609,778
   Restricted cash                    20,012        20,012
   Short-term investments            248,000            --
   Accounts receivable, net
    of allowances of $26,820
    at June 30, 2010 and
   $8,400 at December 31,
    2009                             274,909       203,211
   Inventories                       830,233       638,350
   Deposits                          189,250       182,010
   Prepaid income taxes                1,442         3,176
   Prepaid expenses and other
    current assets                    71,271        86,563
                               -------------  ------------

   Total current assets            3,312,471     2,743,100
                               -------------  ------------


  PROPERTY AND EQUIPMENT, NET        222,425       249,465
                               -------------  ------------

  OTHER ASSETS

   Intangible assets, net            206,710       231,026
                               -------------  ------------

   TOTAL ASSETS                  $ 3,741,606   $ 3,223,591
                               =============  ============

        LIABILITIES AND
      STOCKHOLDERS' EQUITY

  CURRENT LIABILITIES
   Accounts payable                $ 355,565     $ 148,087
   Accrued employee
    compensation                     131,433       105,824
   Accrued professional fees
    and other                        176,331       271,926

   Deferred revenue                   19,649         8,058
                               -------------  ------------

   Total current liabilities         682,978       533,895
                               -------------  ------------

  LONG TERM LIABILITIES

   Deferred revenue                   11,510         1,609
                               -------------  ------------

   TOTAL LIABILITIES                 694,488       535,504
                               -------------  ------------

  COMMITMENTS AND
   CONTINGENCIES

  STOCKHOLDERS' EQUITY
   Series A convertible
    preferred stock, $.01 par
    value; 313,960 designated
    shares; 266,492 shares
    issued and outstanding on
    June 30, 2010 and 152,213
    shares on December 31,
    2009 (Liquidation value
    of $3,064,658)                     2,665         1,523
   Series B convertible
    preferred stock, $.01 par
    value; 279,256 designated
    shares; 88,711 shares
    issued and outstanding on
    June 30, 2010 and 62,039
    shares on December 31,
    2009 (Liquidation value
    of $1,667,767)                       887           620
   Common stock, $.01 par
    value; 20,000,000 shares
    authorized; 2,621,824
    shares issued and
    outstanding on June 30,
    2010 and 2,328,426 shares
    issued and outstanding on
    December 31, 2009                 26,218        23,284
   Warrants to acquire
    preferred stock and
    common stock                   1,132,675     1,352,165
   Additional paid-in capital     11,911,626     9,297,115

   Accumulated deficit          (10,026,953)   (7,986,620)
                               -------------  ------------

   Total stockholders' equity      3,047,118     2,688,087
                               -------------  ------------
   TOTAL LIABILITIES AND
    STOCKHOLDERS' EQUITY         $ 3,741,606   $ 3,223,591
                               =============  ============
CONTACT:  Pressure BioSciences, Inc.
          Investor Contacts:
          Richard T. Schumacher, President & CEO
          R. Wayne Fritzsche, Chairman
          Joseph L. Damasio, Jr., Controller
          (508) 230-1828